BUDGET IMPACT ANALYSIS OF TRASTUZUMAB EMTANSINE FOR RESIDUAL INVASIVE HER2-POSITIVE BREAST CANCER IN ARGENTINA

被引：0
|
作者：
Penayo, N. [1 ]
Peredo, S. [2 ]
Olivera, M. S. [1 ]
Weissberg, A. [1 ]
Tellechea, F. [1 ]
Saenz, V [1 ]
机构：
[1] F Hoffmann La Roche Ltd, Tigre, Argentina
[2] F Hoffmann Roche Ltd, Buenos Aires, DF, Argentina
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN62
引用
收藏
页码：S433 / S433
页数：1
相关论文
共 50 条
  • [21] Trastuzumab emtansine: a game changer in HER2-positive early breast cancer
    Mano, Max S.
    FUTURE ONCOLOGY, 2020, 16 (32) : 2595 - 2609
  • [22] Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
    Recondo, Gonzalo, Jr.
    de la Vega, Maximo
    Galanternik, Fernando
    Diaz-Canton, Enrique
    Amadeo Leone, Bernardo
    Leone, Jose Pablo
    CANCER MANAGEMENT AND RESEARCH, 2016, 8 : 57 - 65
  • [23] NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer
    Elsada, Ahmed
    Doss, Sally
    Robertson, Janet
    Adam, E. Jane
    LANCET ONCOLOGY, 2016, 17 (02): : 143 - 144
  • [24] Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
    Yang, Jiangping
    Han, Jiaqi
    Zhang, Yalan
    Muhetaer, Muhelisa
    Chen, Nianyong
    Yan, Xi
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [25] A BUDGET-IMPACT ANALYSIS OF ADJUVANT PERTUZUMAB AND TRASTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER
    Walter, E.
    Lazic-Peric, A.
    VALUE IN HEALTH, 2018, 21 : S26 - S26
  • [26] Ado-Trastuzumab Emtansine (Kadcyla) for HER2-Positive Metastatic Breast Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2013, 55 (1425): : 75 - 76
  • [27] Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence?
    Ricci, Francesco
    Le Tourneau, Christophe
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (01)
  • [28] Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
    Boyraz, Baris
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Babacan, Taner
    Roach, Emir C.
    Kizilarslanoglu, Muhammet C.
    Petekkaya, Ibrahim
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (04) : 405 - 414
  • [29] Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
    Iwata, Hiroji
    Xu, Binghe
    Kim, Sung-Bae
    Chung, Wei-Pang
    Park, Yeon Hee
    Kim, Min Hwan
    Tseng, Ling-Ming
    Chung, Chi-Feng
    Huang, Chiun-Sheng
    Kim, Jee Hyun
    Chiu, Joanne Wing Yan
    Yamashita, Toshinari
    Li, Wei
    Egorov, Anton
    Nishijima, Soichiro
    Nakatani, Shunsuke
    Nishiyama, Yuji
    Sugihara, Masahiro
    Cortes, Javier
    Im, Seock-Ah
    CANCER SCIENCE, 2024, 115 (09) : 3079 - 3088
  • [30] The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer
    Véronique Diéras
    Thomas Bachelot
    Targeted Oncology, 2014, 9 : 111 - 122
12345